82 results about "Tranquilizing Agents" patented technology

The present invention provides apparatuses and methods to safely and economically deliver infusion fluid to a patient during a medical procedure. The infusion fluid may be a sedative, analgesic, amnestic or other pharmaceutical agent (drug) for alleviating a patient's pain and anxiety before, during and / or after a medical or surgical procedure. In general the apparatus comprises a microprocessor-based controller that receives inputs from a plurality of physiological monitors attached to a patient. The system controller processes the data from the physiological monitors and based upon a fluid infusion algorithm delivers infusion fluid to a patient. The physiological monitors monitor the patient throughout the course of the procedure and depending upon the health of the patient, drug delivery may be adjusted to optimize the procedure while ensuring the patient's health is maintained. Functionality detectors such as an occlusion sensor, air-in-line sensor and a fluid detection sensor alert a clinician to such hazards as a pressure build up in the infusion line, air-bubbles in the infusion line, and the absence of fluid in the infusion line.

The present invention provides apparatuses and methods to safely and economically deliver infusion fluid to a patient during a medical procedure. The infusion fluid may be a sedative, analgesic, amnestic or other pharmaceutical agent (drug) for alleviating a patient's pain and anxiety before, during and / or after a medical or surgical procedure. In general the apparatus comprises a microprocessor-based controller that receives inputs from a plurality of physiological monitors attached to a patient. The system controller processes the data from the physiological monitors and based upon a fluid infusion algorithm delivers infusion fluid to a patient. The physiological monitors monitor the patient throughout the course of the procedure and depending upon the health of the patient, drug delivery may be adjusted to optimize the procedure while ensuring the patient's health and pain level are maintained.

A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary solid dosage, and prepared for oral administration before bedtime. Usually, structure is configured to initially release a calmative or other sleep-compatible substance by prompt dissolution. The initial release is followed by a specific period of delay, which in basic formulations entails no release of any drug, and which allows a nominal interval of sleep. At the terminus of the delay, a final agent is released to induce wakeup. Incorporation of agents of opposite action within a unitary dosage form renders utility which is uniquely appropriate to the invention. In a preferred embodiment, delay of release and final delivery of wakeup agent are arranged by a dialysis membrane which eventually bursts as a result of osmotic pressure generated by a hydrophilic core.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and / or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.

The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation.The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.

Hypodermic syringes with multiple needles are used to practice a method of calming psychiatric patients. In accordance with one embodiment of the invention generally used to calm violent adult patients, the syringe has a first barrel containing an antipsychotic, a second barrel containing a sedating antihistamine and a third barrel containing an antianxiety sedative. Each barrel also has a separate projecting needle and contains a piston. A common operator, preferably in the form of a plunger simultaneously pushes all of the pistons so that the patient receives three injections simultaneously. For children, a second embodiment of the syringe includes two barrels instead of three, each barrel containing a separate medication. In each embodiment the syringe is packaged in a manually openable plastic envelope with a safety cap over the needles.

Disclosed is drug delivery for facilitating medical and / or procedures that are performed without “general anesthesia,” which is also described in the specification as the state of patient “unconsciousness” resulting from a drug administered by an anesthetist or anesthesiologist. Mixtures of sedative and analgesic drugs are adapted for safe and effective administration by devices to provide and maintain drug infusions that do not push the patient into unconsciousness and / or general anesthesia. Drug delivery devices are also disclosed that include the use of stored parameters and / or values that correlate to drug mixture delivery during a procedure, and a patient health monitor to measure and send signals regarding a patient health condition to a processor.

The present invention comprises a user interface for systems and methods for sedation and analgesia delivery. The user interface receives input from a user of a sedation and analgesia delivery system and relays information regarding the system, the administration of sedation and analgesia, physiological conditions to the user in a context sensitive manner. The information relayed may be displayed to the user on a touch sensitive screen or multi-layer display device. The display may be segregated geographically or may be color coded on the display device where the geographic location or color of the displayed information relates further information to the user.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

The present invention includes systems and methods for decreasing the pain and discomfort commonly associated with endoscopic procedures, where such procedures may be performed with lower dosage levels of sedative and analgesic drugs. The invention includes use of an anesthetic collar coupled to an endoscope with a flexible shaft. The anesthetic collar allows lubricants, local anesthetics, dyes, and / or other desirable fluids to be passed through the existing lumen of the flexible shaft into an annulus, where the fluid may be distributed through expulsion pores into the gastrointestinal tract. Utilizing the existing lumens found in endoscopes, the present invention allows those fluids that may reduce the pain and discomfort associated with endoscopies such as, for example, local anesthetics and lubricants, to be distributed in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, where such fluids may reduce the drug level requirements for sedative and analgesic agents. Alternatively, the endoscope may be redesigned for streamlined integration with the anesthetic collar or to accomplish the same function of distributing local anesthetics and lubricants, in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, The invention can also be used with endoscopes without existing lumens.

The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and / or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.

A pharmaceutical composition comprising: (a) meloxicam or a pharmaceutically acceptable salt thereof; and (b) one or more additional pharmaceutically active compounds selected from antacids, sedatives, and central nervous system stimulants, and the use of such composition of an inflammatory disease, symptoms of an inflammatory disease, including various symptoms thereof, and / or headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction and / or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Solid tablets or gel capsules comprising acetaminophen and an agent that promotes glutathione production that mitigates adverse hepatic effects of acetaminophen. The glutathione production promoter is preferably n-acetylcysteine or other mercapto-2-amino alkyl carboxylic acid having glutathione production promoting properties. A preferred composition comprises acetaminophen (200 mg to 750 mg) and N-acetylcysteine (200 mg to 600 mg). Alternatively and / or in addition to N-acetylcysteine the composition can contain at least one of methionine and cysteine. Preferred compositions can contain at least one of an opiate (or synthetic equivalent), an antihistamine, an antiemetic, and a sedative. Physical encapsulation of the ingredients optionally with or in place of a fragrance is used to make the composition more acceptable to patients by mitigating noxious properties of the glutathione production promoter. Preferably, the compositions are prepared for patient self administration in tablet or gel capsule form wherein the patients can take the medication without the need for close oversight of a medical caregiver.

The invention relates to a preparation method of a feedstuff additive that biologically transformed from natural bioactive components, and is characterized in preparing feedstuff additive from natural vegetation fermenting technique. The preparation method is that Aspergillus niger and Bacillus subtilis are respectively cultivated, a powder and product can be acquired by fermenting liquid or solid Dandelion with Aspergillus niger or Bacillus subtilis, or by fermenting liquid or solid milk veteh with Bacillus subtilis, and the three dry powders are mixed, sieved, thus acquiring a mixed dry powder end product, i.e., natural vegetation drug feedstuff additive. The invention has the advantages that can improve total contents of flavone and Chlorogenic acid by transforming natural vegetation drug, and decrease the toxic effects and side effects of the natural vegetation. In condition that feedstuff is not added with such harmful additives as antibiotic, quietive and hormone, the adding of the additive of the invention can improve the weight of pig and chicken by 5 to 10 percent, and increase the feedstuff transforming ratio by 5 to 8 percent.

The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.

The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative.

The invention discloses a method for detecting the residue quantity of depressant medicine in aquatic products. The method can be used for detecting the medicine residue of 24 depressant medicines, and comprises the following steps of performing sample pretreatment; after sample homogenizing, adding salting-out agents; using acetonitrile for extraction; after concentration, using 50-percent (v / v)methanol-water solution for reaching the constant volume; then, using acetonitrile saturated n-hexane for purification; performing ultra-high performance liquid chromatography-quadrupole / static fieldorbitrap high-resolution mass spectrometric detection, wherein the chromatographic column uses ACQUITY UPLC BEHC18; using gradient elution; preparing mixed depressant medicine standard work solutionsof different concentrations; respectively performing mass spectrometric detection to obtain each depressant linear equation and corresponding decision coefficients; substituting the chromatographic peak area of the sample into the depressant medicine standard work solution equation to obtain the detection result. The method has the advantages that the operation is simple; the precision is high; the accuracy is high; in addition, the applicable depressant types are more.

The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

The invention relates to a method for determining residual medicaments in mutton, and in particular relates to a method for determining multiple sedative type medicaments in mutton at the same time. The residual sedative type veterinary medicaments refer to zolpidem, haloperidol, chlordiazepoxide, promethazine, nitrazepam, chlorpromazine hydrochloride, perphenazine, fluphenazine hydrochloride, clonazepam, xylazine hydrochloride, propionylpromazine, carazolol, acepromazine, droperidol and azaperone. The method has the advantage that the residual amounts of 15 types of sedative type medicaments in mutton are determined through high-resolution liquid chromatography-tandem mass spectrometry. The method is high in sensitivity and high in recovery rate, and can meet the detection requirements on veterinary medicaments.

A rodent trap is provided as well as a method for more humanely trapping the rodent. The trapping device allows the rodent to enter or step onto a receiving area. A bait held within or on the device includes a natural herbal substance in an effective amount to operate as a calming agent to relax the rodent. Most preferred as a calming agent is Valerian Root.

The invention discloses a phenyl acetic vinegar compound shown in the general formula (I), wherein A represents CnHmFxClyBrz and at least has an alkyl group, a naphthenic group, an olefine group or an alkyne group which is substituted by a halogen atom; n in the A is 1-6, m is 0-2n, x is 0-2n, y is 0-2n, z is 0-2n, m+x+y+z=2n+1, 2n-1 or 2n-3, and x+y+z >= 1; and R1, R2 and R3 represent alkyl groups of C1-C6, olefine groups of C2-C6 or alkyne of C2-C6 which are respectively independent. The invention also relates to a medicine composition taking the compound as an active component and the application of the compound and the medicinal composition in an anesthetization maintaining, inducement and hypnotizing calmative of people or animals.

The invention provides a compound preparation for preventing and treating heat stress syndrome of beef cattle. The compound preparation comprises the following medicated raw materials in parts by weight: 200 to 300 parts of agastache, 200 to 300 parts of rhizoma atractylodis, 100 to 200 parts of hoantchy root, 100 to 200 parts of baical skullcap root, 100 to 150 parts of costustoot and 100 to 150 parts of dried orange peel; all the medicated raw materials are smashed and then mixed well. The invention further provides a preparation method and a use method of the compound preparation for preventing and treating heat stress syndrome of beef cattle. The compound preparation is based on the theory of 'Chinese veterinary medicines', is mainly formed by compounding Chinese herbal medicines, is used for replacing frequently-used antibiotics, sedative and other medicated premix to prevent and treat heat stress response of beef cattle, and has the advantages of safety, no residue, no toxicity or harm to animals, and the like. The compound preparation is particularly applicable to high-temperature and high-humidity environments in the south in summer and can be used for preventing and treating heat stress response of growing beef cattle and fattening beef cattle in summer.

The invention discloses a green tea health care product for treating insomnia and a preparation method thereof, and aims to solve the problems that by adopting the sedative to treat the insomnia, the toxic and side effect can be produced on the human nerves and visceral organs, the sleeping quality can't be effectively improved, the drug resistance and dependence can be caused through long-time use. The green tea health care product includes the following components of green tea, gastrodia elata, bamboo juice, smoked plum, lotus seed, wild jujube seed and organ peel. The green tea health care product take the green tea and the gastrodia elata as the main components without the addition of the bamboo juice, the smoked plum, the lotus seed, the wild jujube seed and the organ peel, and the components interact to achieve the functions of soothing nerves and regulating internal circulation, so as to effectively improve the sleeping quality of the patients. The components of the green tea health care product are all serve both as drug and food and have no toxic and side effect, the drug resistance and dependence can't be caused by long-time use of the components of the green tea health care product, at the same time, the self-immunity is remarkably improved, the human metabolism is accelerated, and the functions of human bodies are improved.

The present disclosure involves a system for monitoring patients, and more specifically post-operative patients receiving narcotics / sedatives / opioids, and a novel apparatus for automatically delivering one or more substances such as a reversing agent, including but not limited to the agent commonly known as naloxone, in response to dangerous respiratory conditions such as respiratory depression or other undesired consequences caused by reaction to another dosage being delivered to the subject.

This invention provides a pharmaceutical and functional food which are made of a safe food ingredient or nutrient which has been used for a long period of time, and which have tranquilizing effect such as anti-anxiety effect, anti-depression effect, and anti-stress effect. The tranquilizer of the invention contains vitamin K as an active ingredient. Vitamin K is preferably menaquinone-4 and / or menaquinone-7. This invention also provides a supplement, health food or functional food for tranquilizing purpose that contains vitamin K as an active ingredient.

Controlled-release therapeutic compositions including melatonin combined with sedative and / or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.

The present invention relates to compounds of formulae IA and IB wherein R1 and R2 are each independently lower alkyl or —(CH2)m—O-lower alkyl, or together with the N atom to which they are attached form a heterocyclic ring; R3 is hydrogen or lower alkyl; R4 is lower alkyl; hetaryl is 3H-imidazole-2,4-diyl or 1H-pyrazole-1,4-diyl; n is 1 or 2; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.